Treatment of bacterially-induced inflammatory diseases
CA 2176237 A1 · Owner: Bristol-Myers Squibb Company · Inventors: Darveau, Richard P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The lipopolysaccharide of bacteria associated with chronic inflammatory diseases is unable to induce expression of leukocyte adhesion molecules, or selectins, on endothelial cells and is also capable of inhibiting the induction of selectin expression by bacteria normally associated with acute endotoxin disease. New approaches to treatment of these diseases and the diagnosis of susceptibility to chronic baterial-associated inflammatory diseases are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 10, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 10, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 10, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.